{"filing":{"accession_number":"0001104659-26-078452","cik":"0001962738","ticker":"CASIF","company_name":"CASI Pharmaceuticals, Inc.","form":"6-K","filing_date":"2026-06-29","report_date":null,"primary_document":"tm2619066d1_6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1962738/000110465926078452/tm2619066d1_6k.htm"},"events":[{"id":14418,"run_id":12839,"accession_number":"0001104659-26-078452","anchor_item_number":null,"event_type":"legal_other","event_domain":"legal","is_material":true,"confidence":0.75,"summary":"CASI Pharmaceuticals announced settlement of an arbitration proceeding with Acrotech Biopharma regarding termination of a license agreement for exclusive commercialization rights to Evomela® in China. The settlement rescinded the purported termination and restored the License Agreement to full force and effect, subject to revised terms including minimum purchase obligations. This is a material legal resolution affecting the Company's rights to a key commercial asset, but does not fit the specific categories of material_litigation (which typically involves lawsuits filed against the registrant or government investigations) or other defined event types; it is a settlement of a contractual dispute that materially affects the Company's business operations and rights.","company_name":"CASI Pharmaceuticals, Inc.","ticker":"CASIF","filing_date":"2026-06-29","form":"6-K","submitted_at":null,"items":null}],"classifications":[{"id":11843,"accession_number":"0001104659-26-078452","item_number":null,"item_title":null,"event_type":"legal_other","event_domain":"legal","is_material":true,"confidence":0.75,"reasoning":"CASI Pharmaceuticals announced settlement of an arbitration proceeding with Acrotech Biopharma regarding termination of a license agreement for exclusive commercialization rights to Evomela® in China. The settlement rescinded the purported termination and restored the License Agreement to full force and effect, subject to revised terms including minimum purchase obligations. This is a material legal resolution affecting the Company's rights to a key commercial asset, but does not fit the specific categories of material_litigation (which typically involves lawsuits filed against the registrant or government investigations) or other defined event types; it is a settlement of a contractual dispute that materially affects the Company's business operations and rights.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-29T10:31:41.800285+00:00","company_name":"CASI Pharmaceuticals, Inc.","ticker":"CASIF","filing_date":"2026-06-29"}]}